Skip to content
ClinCalc Pro
Menu
Strong opioid

Oxycodone hydrochloride

Brand names: OxyNorm, OxyContin, Shortec, Longtec

Oxycodone is a strong opioid for moderate-to-severe pain, including post-operative and cancer pain, available in immediate- and modified-release forms.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 5 mg every 4 to 6 hours in opioid-naive adults, then titrate. §4.2, verbatim: 'The usual starting dose for opioid naïve patients or patients presenting with severe pain uncontrolled by weaker opioids is 5 mg, 4-6 hourly.' The SPC's own heading for this regimen is 'Adults over 18 years', and: 'Oxycodone solution should be taken at 4-6 hourly intervals.'
Route: Oral — this SPC is the 5 mg/5 mL sugar-free oral SOLUTION (immediate-release). 'Oxycodone is for oral use.' SCOPE — this draft covers the page's primary route and formulation, oral immediate-release, only. This bundle contains NO intravenous and NO subcutaneous regimen, and NO modified-release (12-hourly) regimen, although this page lists 'PO/IV/SC' and names OxyContin and Longtec. The SPC supplies only a conversion ratio for the parenteral route ('2 mg of oral oxycodone is equivalent to 1 mg of parenteral oxycodone') and no parenteral starting dose, so the page's 'IV/SC: 1–10mg every 4h or 0.5–1 mg/h infusion' and 'PO MR: 10mg every 12h' figures are NOT drafted here.
Frequency: Every 4 to 6 hours
Max: No maximum dose is stated in either fetched label. Both are titration labels: the UK SPC gives a starting dose and instructs that 'Patients should be titrated to pain relief unless unmanageable adverse drug reactions prevent this', and the US label likewise gives only a starting range ('5 to 15 mg every 4 to 6 hours') with the instruction to 'Use the lowest effective dosage for the shortest duration of time'. The only numeric limits anywhere in the fetched text are the halved starting dose in renal or hepatic impairment and the morphine-equivalence conversion ratios — neither is a ceiling, and neither is reproduced here as one.
SCOPE: oral immediate-release adult analgesia from the UK SPC for the 5 mg/5 mL oral solution; no IV, SC or modified-release figure exists in this bundle. || STRENGTH OF THE PRODUCT THIS SPC COVERS: 5 mg per 5 mL (i.e. 1 mg/mL) — the 5 mg starting dose is 5 mL of this solution. || TITRATION, verbatim: 'The dosage is dependent on the severity of the pain, and the patient's previous history of analgesic requirements. Generally, the lowest effective dose for analgesia should be selected... The correct dosage for any individual patient is that which controls the pain and is well tolerated throughout the dosing period. Patients should be titrated to pain relief unless unmanageable adverse drug reactions prevent this.' The dose 'should then be carefully titrated, as frequently as once a day if necessary, to achieve pain relief.' || CONVERSION FROM ORAL MORPHINE, verbatim: '10 mg of oral oxycodone is equivalent to 20 mg of oral morphine. It must be emphasised that this is a guide to the dose of Oxycodone solution required. Inter-patient variability requires that each patient is carefully titrated to the appropriate dose.' || ORAL TO PARENTERAL RATIO (a conversion ratio only — the SPC gives NO parenteral starting dose), verbatim: '2 mg of oral oxycodone is equivalent to 1 mg of parenteral oxycodone. It must be emphasised that this is a guide to the dose required.' || ELDERLY, verbatim: 'A dose adjustment is not usually necessary in elderly patients... compared with younger adults, the clearance of oxycodone is only slightly reduced. No untoward adverse drug reactions were seen based on age, therefore adult doses and dosage intervals are appropriate.' || BEFORE STARTING, verbatim: 'Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with oxycodone in order to minimise the risk of addiction and drug withdrawal syndrome.' Duration: 'Oxycodone should not be used for longer than necessary. In common with other strong opioids, the need for continued treatment should be assessed at regular intervals.' || NON-MALIGNANT PAIN, verbatim: 'Opioids are not first line therapy for chronic non-malignant pain, nor are they recommended as the only treatment. Types of chronic pain which have been shown to be alleviated by strong opioids include chronic osteoarthritic pain and intervertebral disc disease.' || PERI-PROCEDURAL, §4.4 verbatim: 'Oxycodone solution should be used with caution pre-operatively and within the first 12-24 hours post-operatively' and 'Patients about to undergo additional pain relieving procedures (e.g. surgery, plexus blockade) should not receive Oxycodone solution for 6 hours prior to the intervention.' || US LABEL CROSS-CHECK (US labelling for IMMEDIATE-RELEASE TABLETS — quoted as a cross-check, not substituted for the UK figure): 'Initiate treatment with oxycodone hydrochloride in a dosing range of 5 to 15 mg every 4 to 6 hours as needed for pain and at the lowest dose necessary to achieve adequate analgesia.' US strengths: 'Immediate-release tablets: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg'. The US label also directs: 'Discuss opioid overdose reversal agents and options for acquiring them with the patient and/or caregiver, both when initiating and renewing treatment', and 'Do not rapidly reduce or abruptly discontinue oxycodone hydrochloride in a physically dependent patient because rapid reduction or abrupt discontinuation of opioid analgesics has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide.' || NOT SUPPORTED BY THIS BUNDLE: the page's parenteral figures, its modified-release figures, the equianalgesic ratio '1.5:1' (the SPC's ratio is 10 mg oral oxycodone = 20 mg oral morphine, i.e. 2:1), the statement that brand-specific MR formulations are not interchangeable, and the routine laxative advice — none of these appears in the fetched sections. Controlled-drug scheduling is likewise not stated in either fetched label.

Paediatric dose

Route: Oral — but the UK SPC does not permit use under 18 years; see notes
Frequency: Not applicable — no paediatric regimen exists in this bundle
NO PAEDIATRIC DOSE EXISTS IN THIS BUNDLE, AND THE UK LABEL REFUSES THE AGE GROUP OUTRIGHT. §4.2, Paediatric population, verbatim: 'Oxycodone solution should not be used in patients under 18 years.' The adult posology is itself headed 'Adults over 18 years'. The US label in this bundle contains no paediatric section at all (no §8.4 was returned), so it neither supports nor bounds paediatric use either. dosePerKg and concentration are therefore both NULL and nothing is fed to the weight calculator.

Dose adjustments

Renal

§4.2, Patients with renal or hepatic impairment, verbatim: 'The plasma concentration in this patient population may be increased. The dose initiation should follow a conservative approach in these patients. The recommended adult starting dose should be reduced by 50% (for example a total daily dose of 10 mg orally in opioid naïve patients), and each patient should be titrated to adequate pain control according to their clinical situation.' §4.4 additionally lists impaired renal function among the conditions in which 'Caution must be exercised'. No eGFR band or threshold appears anywhere in the fetched text.

Hepatic

The same §4.2 sentence applies: 'The recommended adult starting dose should be reduced by 50% (for example a total daily dose of 10 mg orally in opioid naïve patients), and each patient should be titrated to adequate pain control according to their clinical situation.' ⚠ But note the harder limit in §4.3: this SPC CONTRAINDICATES oxycodone in 'moderate to severe hepatic impairment', so the 50% reduction applies only to mild impairment. No Child-Pugh threshold is given.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

US labelling (FDA)

Reference — US labelling, may differ from UK

Oxycodone hydrochloride tablets should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. (2.1) Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals. Reserve titration to higher doses of oxycodone hydrochloride for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. (2.1, 5) Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an …

Source: US FDA prescribing information (openFDA / DailyMed), label dated 2026-01-14. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.

Contraindications

  • Hypersensitivity to oxycodone or to any of the excipients listed in section 6.1
  • Severe respiratory depression with hypoxia
  • Paralytic ileus
  • Acute abdomen
  • Delayed gastric emptying
  • Severe chronic obstructive lung disease
  • Cor pulmonale
  • Severe bronchial asthma
  • Elevated carbon dioxide levels in the blood
  • Moderate to severe hepatic impairment
  • Chronic constipation

Side effects

  • Very common: somnolence, dizziness, headache
  • Very common: constipation, nausea, vomiting
  • Very common: pruritus
  • Common: anxiety, confusional state, depression, insomnia, nervousness, abnormal thinking, abnormal dreams
  • Common: tremor, lethargy, sedation
  • Common: dyspnoea, bronchospasm, cough decreased
  • Common: abdominal pain, diarrhoea, dry mouth, dyspepsia
  • Common: decreased appetite
  • Common: rash, hyperhidrosis
  • Common: asthenia, fatigue
  • Uncommon: respiratory depression, hiccups
  • Uncommon: hypersensitivity; dehydration
  • Uncommon: agitation, affect lability, euphoric mood, hallucinations, decreased libido, disorientation, mood altered, restlessness, dysphoria
  • Uncommon: amnesia, convulsion, hypertonia, hypoaesthesia, involuntary muscle contractions, speech disorder, syncope, paraesthesia, dysgeusia, hypotonia
  • Uncommon: visual impairment, miosis; vertigo
  • Uncommon: palpitations (in the context of withdrawal syndrome), supraventricular tachycardia; vasodilatation, facial flushing
  • Uncommon: dysphagia, flatulence, eructation, ileus, gastritis
  • Uncommon: increased hepatic enzymes, biliary colic
  • Uncommon: dry skin, exfoliative dermatitis
  • Uncommon: urinary retention, ureteral spasm
  • Uncommon: erectile dysfunction, hypogonadism
  • Uncommon: malaise, oedema, peripheral oedema, thirst, pyrexia, chills
  • Rare: hypotension, orthostatic hypotension; urticaria
  • Frequency not known: anaphylactic and anaphylactoid reaction; aggression; drug dependence; hyperalgesia; central sleep apnoea syndrome; dental caries; cholestasis; amenorrhoea; neonatal drug withdrawal syndrome; opioid tolerance; opioid withdrawal syndrome
  • §4.8 is truncated at the source-fetch limit, so this list may be incomplete

Monitoring

  • Respiratory depression — §4.4, verbatim: 'The primary risk of opioid excess is respiratory depression'
  • If co-prescribed with benzodiazepines or related sedatives: 'The patient should be followed closely for signs and symptoms of respiratory depression and sedation', and inform patients and carers to watch for these symptoms
  • Sleep-related breathing disorders — opioids increase the risk of central sleep apnoea in a dose-dependent fashion; 'In patients who present with CSA, consider decreasing the total opioid dosage'
  • Bowel function — discontinue immediately if paralytic ileus is suspected or occurs; after abdominal surgery do not use 'until the physician is assured of normal bowel function'
  • Tolerance, dependence, addiction and withdrawal — agree a plan for ending treatment before starting, keep 'frequent contact between the physician and the patient to evaluate the need for continued treatment', and taper rather than stop abruptly
  • Reassess pain control regularly — 'In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered'
  • Constipation and nausea: 'Constipation may be prevented with an appropriate laxative. If nausea and vomiting are troublesome, oxycodone may be combined with an anti-emetic'

Clinical monograph

How it works

It is an agonist at opioid receptors (mainly mu), reducing pain perception and transmission.

Prescribing in practice

  • Start low — especially in older patients and renal or hepatic impairment — and co-prescribe a regular laxative; use equivalence tables when switching opioids.
  • It is a controlled drug with dependence and diversion potential; additive respiratory depression with other CNS depressants.
  • Immediate-release and modified-release forms are not interchangeable dose-for-dose, and modified-release tablets must not be crushed.

Monitoring

Review pain relief, sedation, bowel habit and signs of dependence; reassess the ongoing need and ensure naloxone access where overdose risk is high.

Counselling the patient

  • It commonly causes constipation — take the laxative provided.
  • Do not combine it with alcohol or other sedatives.
  • Take it exactly as prescribed; it can be habit-forming, and do not crush modified-release tablets.

Evidence & guidelines

A strong opioid for moderate-to-severe pain, used within opioid-stewardship principles with laxative co-prescription.

Reference: NICE CG140; UK FPM; Palliative care formulary; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.